Comparison · NCT02270957-79ea4969
Abatacept vs Placebo: 4 Point Improvement in the SLE Disease Activity Index (SLEDAI)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Abatacept vs Placebo: 4 Point Improvement in the SLE Disease Activity Index (SLEDAI). Trial comparisons, record NCT02270957-79ea4969. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02270957-79ea4969
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.29 | 0.161 | 0.466 | wilson | |
| Risk in group 2 | 0.229 | 0.121 | 0.39 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0618 | -0.145 | 0.268 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.27 | 0.559 | 2.89 | log | |
| Odds ratio, group 1 over group 2 | 1.38 | 0.457 | 4.17 | log | |
| Number needed to treat, for one more participant with the outcome on Abatacept than on Placebo | 16.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abatacept | Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.~Abatacept | 9 | 31 | OG000 |
| Group 2 | Placebo | Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.~Placebo | 8 | 35 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- POST_HOC
- Title
- 4 Point Improvement in the SLE Disease Activity Index (SLEDAI)
- Description
The SLEDAI is a discontinuous scoring system that weights disease activity not by severity of individual symptoms but by the weighting of organs. This makes it less robust for comparing one group of patients to another, but it is quite useful to gave numbers of patients with improvement, since to lower the score a rigorous improvement must be documented
- Time frame
- Comparison of Baseline to 6 months
- Population
- Full Analysis Set of all randomized patients
Source ClinicalTrials.gov
Trial
- Title
- Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
- NCT number
- NCT02270957
- Phases
- PHASE2
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Abatacept, Placebo
- Lead sponsor
- Oklahoma Medical Research Foundation
- Results first posted
- 2020-11-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02270957?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02270957-79ea4969